Figure 1

Overall survival after EBRT as single modality. (p<0.001 comparing PSA progression during initial HT vs. no PSA progression/no HT in log-rank test).
Overall survival after EBRT as single modality. (p<0.001 comparing PSA progression during initial HT vs. no PSA progression/no HT in log-rank test).